Bleeding rates raise questions about Pradaxa dosing in elderly
This article was originally published in Scrip
Executive Summary
Further data on bleeding rates with Boehringer Ingelheim's direct thrombin inhibitor Pradaxa (dabigatran) in the elderly in the US have raised concerns over the one-size-fits-all dose regimen approved by the FDA.